Pharmacogenetics in heart failure: promises and challenges

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656560903025171PMID 19558337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Cardiovascular Disease

  2012cited by this paper
• The largest prospective warfarin-treated cohort supports genetic forecasting.

  2009cited by this paper
• Pharmacogenomics: the promise of personalized medicine for CNS disorders.

  2009cited by this paper
• Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure

  2009cited by this paper
• Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy.

  2009cited by this paper
• Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders

  2009cited by this paper
• Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels

  2009cited by this paper
• Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Pharmacogenetics in drug discovery and development: a translational perspective

  2008cited by this paper
• Emerging role of pharmacogenomics in heart failure

  2008cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡

  2008cited by this paper
• Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

  2008cited by this paper
• From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure

  2008cited by this paper
• Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses.

  2008cited by this paper
• Mapping the Genetic Architecture of Gene Expression in Human Liver

  2008cited by this paper
• Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta‐analysis

  2008cited by this paper
• Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment.

  2008cited by this paper
• Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

  2008cited by this paper
• Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan

  2008cited by this paper
• Redefining quality--implications of recent clinical trials.

  2008cited by this paper
• From Darwin's finches to canaries in the coal mine--mining the genome for new biology.

  2008cited by this paper
• Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies

  2008cited by this paper
• Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis.

  2007cited by this paper
• Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.

  2007cited by this paper
• Universal risk factors for multifactorial diseases

  2007cited by this paper
• Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project

  2007cited by this paper
• A Pharmacogenomics Primer

  2007cited by this paper
• Genomewide association analysis of coronary artery disease.

  2007cited by this paper
• Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure.

  2007cited by this paper
• Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol.

  2007cited by this paper
• Pharmacogenetics of beta-blockers.

  2007cited by this paper
• Arg389Gly-&bgr;1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol

  2007cited by this paper
• Mid-myocardial fibrosis by cardiac magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic dysfunction.

  2007cited by this paper
• Drug-Induced Epigenetic Changes Produce Drug Tolerance

  2007cited by this paper
• Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.

  2007cited by this paper
• Pharmacogenetics of the human beta-adrenergic receptors

  2007cited by this paper
• Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene.

  2007cited by this paper
• Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.

  2006cited by this paper
• Global variation in copy number in the human genome

  2006cited by this paper
• A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

  2006cited by this paper
• Genetics in heart failure: where are we headed?

  2006cited by this paper
• Telomere length of circulating leukocytes is decreased in patients with chronic heart failure.

  2006cited by this paper
• Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.

  2006cited by this paper
• The publication process itself was the major cause of publication bias in genetic epidemiology.

  2006cited by this paper
• Genetics in heart failure: where are we headed?

  2006cited by this paper
• Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

  2005cited by this paper
• Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.

  2005cited by this paper
• The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy.

  2005cited by this paper
• The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure *

  2005cited by this paper
• β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure

  2005cited by this paper
• Clinical and genetic issues in familial dilated cardiomyopathy.

  2005cited by this paper
• Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

  2005cited by this paper
• NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

  2005cited by this paper
• The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.

  2005cited by this paper
• Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy

  2004cited by this paper
• Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004influential reference
• Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.

  2004cited by this paper
• Beta‐adrenergic receptor blockade and the angiotensin‐converting enzyme deletion polymorphism in patients with chronic heart failure

  2004cited by this paper
• β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

  2003cited by this paper
• Pharmacology and physiology of human adrenergic receptor polymorphisms.

  2003cited by this paper
• The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and Abnormalities

  2003cited by this paper
• An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study

  2003cited by this paper
• Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

  2002cited by this paper
• An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy.

  2002cited by this paper
• Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure.

  2002cited by this paper
• The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.

  2001cited by this paper
• Pharmacogenetic Interactions Between &bgr;-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure.

  2000cited by this paper
• Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators.

  2000cited by this paper
• Mechanistic and clinical rationales for using beta-blockers in heart failure.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group.

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

  1998cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.

  1996cited by this paper
• Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators.

  1995cited by this paper

• Influence of angiotensin II type 1 receptors and angiotensin-converting enzyme I/D gene polymorphisms on the progression of Chagas’ heart disease in a Brazilian cohort: Impact of therapy on clinical outcomes

  2024cites this paper
• Acute Responses of Cardiac Biomarkers to Intermittent and Continuous Exercise Are Related to Age Difference but Not I/D Polymorphism in the ACE Gene

  2020cites this paper
• Influence of Angiotensin-Converting-Enzyme Gene Polymorphism on Echocardiographic Data of Patients with Ischemic Heart Failure

  2016cites this paper
• Endovascular aneurysm repair: a perioperative perspective

  2012cites this paper
• Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics

  2011cites this paper
• Pharmacogenomics of &bgr;-Adrenergic Receptor Physiology and Response to &bgr;-Blockade

  2011cites this paper
• Pharmacoepigenetics in Heart Failure

  2010cites this paper
• Pharmacoepigenetics in Heart Failure

  2010cites this paper
• New insight into the association among atrial fibrillation, electrophysiological remodeling, and the ACE insertion/deletion polymorphism—Toward a more patient-tailored therapy?

  2009cites this paper
• New insight into the association among atrial fibrillation, electrophysiological remodeling, and the ACE insertion/deletion polymorphism--toward a more patient-tailored therapy?

  2009cites this paper